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Summary: Although the changes in urinary glycosaminoglycans have been investigated in several endocrino-
pathies, no information was hitherto available on the content and composition of urinary glycosaminoglycans
in hypothyroidisin. Urinary glycosaminoglycans were therefore investigated in patients with hypo thy roidism
and in healthy subjects. The total daily excretion of urinary glycosaminoglycans was found to be significantly
increased (by 41 %) in hypothyroidism. Two electrophoretic bands were always detected in both examined
groups: a major band of chondroitin sulphate and a minor band of heparan sulphate. Heparan sulphate and
chondroitin sulphate levels were respectively 114% and 42% higher in patients with hypothyroidism than in
controls. The respective increases in chondroitin-4-sulphate and chondroitin-6-sulphate were 31% and 41%.
The relative quantities of chondroitin-4-sulphate, dermatan sulphate, chondroitin-6-sulphate and non-sul-
phated chondroitin sulphate were unchanged in the two examined groups. The changes observed in the levels
of the excreted glycosaminoglycans may reflect the altered metabolism of connective tissue in hypothyroidism.
Introduction , T r r or» i. j ^ ^ ^by Watson & Pearce, who demonstrated that the
Glycosaminoglycans are widely distributed in human mucinous dermal substance which accumulated in
tissues, reaching high concentration in connective tis- affected areas of a patient with localized pretibial
sue ground substance, synovial fluid, hyaline cartilage myxoedema contained increased amounts of hyal-
and cornea (1). Urinary glycosaminoglycans represent uronic acid and chondroitin sulphates as compared
heterogenous mixture of partially depolymerized and with unaffected skin (4). In generalized myxoedema,
partially desulphated products of tissue glycosami- which is due to hypothyroidism, an increase of hyal-
noglycans. Most investigations indicate that urinary uronic acid and sulphated glycosaminoglycans was
glycosaminoglycans originate from the plasma by glo- observed in the tissues. This is due to decreased ca-
merular filtration, although part of the heparan sul- tabolism of hyaluronic acid and an increased rate of
phate fraction may originate from renal tissue (2, 3). synthesis of sulphated glycosaminoglycans (5, 6).
Because urinary glycosaminoglycans are derived from ^ , , , ,. , ,
,™ . " V s *· * j· r *t · Because to our knowledge no studies have been re-different types of connective tissue, studies of their , . . . , . · ^ -^f
 t , ., . r / .. , ported on urinary glycosaminoglycans m patients withexcretion should provide information on the meta- f , .,. J.J _ ö *
u r * * 'r*t *· hypothyroidism, it was of interest to perform a com-bohc status of these tissues. . . .' . . . , . .,parative investigation on glycosaminoglycans in the
Glycosaminoglycan and proteoglycan metabolism is urine of these subjects. The present paper reports the
influenced by a number of hormones. The perturba^ detailed quantitative and qualitative analysis of uri-
tions in glycosaminoglycan metabolism seen in asso- nary glycosaminoglycans in patients with hypothy-
ciation with thyroid disease were first characterized roidism.
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Materials and Methods
Patients (n = 23, female) with hypothyroidism (average age
34 ± 3 years) were studied. All diagnoses were confirmed by
the assay of thyroxine and triiodothyronine concentrations.
These patients were not treated before urine collection and
except for thyroid dysfunction they had no other diseases.
Reference samples (n = 20) were obtained from adult females
(average age 33 ± 7 years) free from acute illness and without
history of chronic disease.
Whole 24 h urine was collected with thymol crystals as a
preservative. Creatinine was measured in all samples by the
method of Polin (7). Only those 24 h urines which gave creati-
nine values within the normal range were accepted.
Chemicals
Chrondroitin AC lyase (EC 4.2.2.5), chondroitin ABC lyase
(EC 4.2.2.4), chondro-6-sulphatase (EC 3.1.6.10), chondro-4-
sulphatase (EC 3.1.6.9), the unsaturated disaccharides as well
as standard chondroitin 4-sulphate from whale cartilage were
from Seikagaku Kogyo Co, Tokyo.
Standard chondroitin 6-sulphate (from shark cartilage) and
dermatan sulphate (from pig skin) were from Miles Laborato-
ries.
Standard heparan sulphate from beef lung was a gift from Prof.
A. L. Horwitz, Dept. of Pediatrics, University of Chicago (this
is a standard prepared in the laboratory of Dr M. B. Mathews
and Dr J. A. Cifonelli, University of Chicago (8)).
Standard hyaluronic acid from human umbilical cord, heparin,
testicular hyaluronidase, heparitinase and Trizma base were
from Sigma.
Cellulose acetate strips (cellogel) and dialysis tubes were a
product of Serva.
Pronase (specific activity 56 300 proteolytic units/g) was from
Calbiochem.
Alcian blue 8 GX was from Windsor Lab. Ltd., Slough, Berk-
shire U. K.
Cetylpyridinium chloride and chondroitin sulphate ex shark
were from Koch-Light Laboratories LTD.
Isolation of glycosaminoglycans from urine
The urine specimens were centrifuged at 3000 g for 15 min and
adjusted to pH 5.0 with acetic acid. By the addition of 0.4 ml
of 50 g/1 cetylpyridinium chloride per 20 ml of urine, glycos-
aminoglycans were precipitated as cetylpiridinium chloride po-
lysaccharide complex at 4 °C overnight. The resulting precipi-
tate was washed twice with ethanol saturated with NaCl, once
with ether then dried. The precipitate was dissolved in 4 ml 0.6
mol/1 NaCl and left for one hour in an iced water bath. Insol-
uble material was removed by centrifugation, and the glycos-
aminoglycans were precipitated from the supernatant by the
addition of 4 vol of absolute ethanol at 4 °C for 12 h. The
precipitate was collected, washed successively with absolute
ethanol and ether and dried in air. The precipitate was dissolved
in 1 ml of 0.1 mol/1 Tris-HCl buffer (pH 7.8) containing 5 mmol
CaCl2 and 0.1 g/1 thymol and the solution was diluted with the
same volume of water. The diluted solution was heated in a
boiling water bath for 30 min, followed by cooling to 50 °C,
then incubated with pronase for two days at 50 °C (0.5 mg
pronase was added on each day of incubation). After cooling
the digest to 4 °C, trichloroacetic acid (300 g/1) was added to
give a final concentration of 100 g/l. The mixture was left to
stand for 4 h at 4 °C then centrifuged at 8000 £ for 15 min at
4°C. Glycosaminoglycans were precipitated from the super-
natant by the addition of 4 vol of ethanol saturated with sodium
acetate at 4 °C for 12 h. The last procedure was repeated twice,
then the precipitate, consisting of crude glycosaminoglycans,
was washed with absolute ethanol and ether and dried in vacuo
over PaOs.
Recovery of chondroit in sulphate a/lded to urine
Various amounts of commercial chondroitin sulphate were
added to urine. The isolation and purification of glycosami-
noglycans were performed as described before. Uronic acid was
determined by the carbazole method of Bitter & Muir (9).
Electrophoresis on cellulose acetate membrane
Two dimentsional electrophoresis on Cellogel membrane was
performed according to Mossman & Patrick (10), using pyri-
dine/acetic acid/water (10 +1 +89, by vol; pH 6.0) for 60
min in the first dimension and 0.1 mol/1 barium acetate pH 7.7
for 130 nun in the second dimension, both with an applied
potential 7.5 V/cm. The strip was then stained with Alcian blue
in methanol/acetic acid/water (50 + 5 + 45, by vol.), destained
with 0.9 rnol/1 acetic acid and further washed with water.
Glycosaminoglycans were identified by comparing their elec-
trophoretic mobilities with those of the standard.
Enzymatic analysis
The further identification of urinary glycosaminoglycans was
based on degradation with testicular hyaluronidase, hepariti-
nase and chondroitinases AC and ABC!). Glycosaminoglycans
isolated from 40 ml of urine were dissolved in 200 μΐ of distilled
water. 50 μΐ of this solution was digested with chondroitinase
ABC (0.08 unit/20 μΐ of Tris HC1 buffer), 50 μ! with chondro-
itinase AC (0.12 unit/20 μΐ of Tris HC1 buffer), 50 μΐ with
heparitinase (0.1 unit/20 μΐ of sodium acetate b ffer) and 50 μΐ
with testicular hyaluronidase (100 μg/20 μΐ of sodium acetate
buffer). Digestion with chondroitinases was carried out in 50
mmol/1 Tris HC1 buffer (pH 8.0) at 37 °C for 2 h (11). Digestion
with heparitinase was performed in 0.2 mol/1 sodium acetate
buffer (pH 7.0) at 37 °C for 12 h (12, 13). Digestion with bovine
testicular hyaluronidase was carried out by using 0.1 mol/1
sodium acetate buffer (pH 5.0) containing 0.15 mol sodium
chloride, for 24 h at 37 °C (14). Following the enzyme digestion
the reaction mixtures were deproteinized with trichloroacetic
acid (final 100 g/I), the resulting precipitate was removed by
centrifugation and the supernatants were dialysed against dis-
tilled water overnight in the cold and lyophilized. The lyophi-
lized material was analysed for glycosaminoglycans by two
dimensional electrophoresis as previously described. The spec-
ificity of enzymes used was examined by digestion and electro-
phoresis of standard glycosaminoglycans.
Other analytical methods
Quantification of glycosaminoglycans separated on cellulose
acetate was carried out according to the procedure offfronowski
et al. (15). The uronic acid content was determined by two
methods: the orcinol method of Brown (16) and the earbazole
method of Bitter & Muir (9). The hexosamine content was
determined by the method of Blumenkrantz & Asboe-Hansen
(17) after hydrolysis of the specimen in 4 mol/1 HC1 for 11 h at
100°C. Glucosamine and galactosamine were estimated sepa-
Enzymes
chondroitin ABC lyase
chondroitin AC lyase
hyaluronidase
„heparitinase
chondro-6-sulphatase
chondro-4-sulphatase
(EC 4.2.2.4)
(EC 4.2.2.5)
(EC 3.2.1.35)
(EC 4.2.2.8)
(EC'3.1.6.10)
(EC;'3.1.6.9)
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rately by Wagner's modification (18) of the method reported
by Blumenkrantz & Asboe-Hansen (17), using an acid hydro-
lysate.
Isomeric chondroitin sulphates, which could not be estimated
by electrophoresis, were determined by the enzymatic method
reported by Saito et al. (11) and Murata et al. (19). Glycosa-
minoglycans isolated from 20 ml of urine were dissolved in 100
μΐ of distilled water and 10 μΐ of this solution was added to
each reaction tube (tab. 1). All reaction mixtures were incubated
for 60 min at 37 °C. The resulting unsaturated disaccharides
were determined with the Morgan-Elson reaction and quantified
as described by Saito et al. in method II with a reference mixture
(11).
Results
Several methods reported by different authors (20,
21, 22) were assessed for the isolation of pure glycos-
aminoglycans from urine. After these experiments,
one combined method of isolation was chosen. The
mean recovery of chondroitin sulphate added was 93.8
± 9.8%. Urinary glycosaminoglycans isolated from
healthy subjects and from hypothyroidism patients
were separated into two fractions by two dimensional
electrophoresis. The main fraction corresponded in
mobility to standard chondroitin-4/6-sulphate and
dermatan sulphate, and was susceptible to treatment
with testicular hyaluronidase, chondroitinase ABC
and chondroitinase AC. Treatment with these en-
zymes resulted in complete disapperance of the band.
This fraction was not susceptible to digestion with
heparitinase. The minor band migrated like standard
heparan sulphate; it was not susceptible to digestion
with testicular hyaluronidase and chondroitinases, but
it was susceptible to heparitinase, which caused the
band to split. Figure 1 shows typical patterns of
Tab. 1. Preparation of reaction mixtures for determination of
isomeric chondroitin sulphates
Number of tube
Reagents
H2O
Tris HC1 buffer pH 8.0
Chondroitinase ABC
(2000 units/1)
Chondroitinase AC
(4000 units/1)
Chondro-6-sulphatase1)
(670 units/1)
Chondro-4-sulphatase1)
(1000 units/1)
Urine sample
1 2 3
Volume added (in
30
15
10
—
—
10
10
10
15
—
15
15
10
10
15
15
10
—
15
10
10
4
μΐ)
40
15
10
—
—
—
10
blank
50
15
—
—
—
—
10
urinary glycosaminoglycans isolated from healthy
subjects (fig. 1 a) and from hypothyroidism patients
(fig. 1 b), as well as the separation of six reference
glycosaminoglycan standards (fig. 1 c) obtained by
two dimensional electrophoresis on cellulose acetate
membranes. Total glycosaminoglycans in urine (ex-
pressed as uronic acid) was determined by three meth-
ods: the carbazole method of Bitter & Muir, the
orcinol method of Brown, and determination after
two dimensional electrophoretic separation according
to Hronowski. The results of these experiments are
shown in table 2 and table 3. The total daily excretion
of glycosaminoglycans, measured by the carbazole
method was 41 % higher in hypothyroidism than in a
control group. Very similar differentiation was found
using the two other methods. Hexosamine analysis of
urinary glycosaminoglycans indicated that changes in
total content of hexosamine in pathologic specimens
HS DS Ch-4/6-S
Ch-4/6-S115 HS
Ch-4/6-S : Ch-4/6-S
: >
· : ί Ο
HA0
\JL
Hep Hep
a
HS
Ch-4/6-S
0
DS
Ο,HAj.
Fig. 1. Two dimensional electrophoresis patterns of urinary glycosaminoglycans of healthy females (a), patients with hypothy-
roidism (b) and an authentic sample composed of chondroitin-4-sulphate (Ch-4-S), chondroitin-6-sulphate (Ch-6-S),
dermatan sulphate (DS), hyaluronic acid (HA), heparan sulphate (HS) and heparin (Hep) — 2.0 μg of each (c). Reference
glycosaminoglycan standards for the run in the first dimension are chondroitin-4/6-sulphate (the fastest), heparan sulphate
and hyaluronic acid (the slowest) and in the second dimension chondroitin-4/6-sulphate (the fastest), dermatan sulphate
and heparan sulphate (the slowest). Conditions for electrophoresis and staining as described under Materials and Methods.
Migration directions are marked with large arrows. Small arrow indicates the application point of the samples.
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Tab. 2. Total urinary glycosaminoglycan content (expressed as uronic acid and hexosamine content) in patients with hypothy-
roidism and in healthy individuals (mean ± SD)
Hypothyroidism
aN = 19
Uronic acid measured by carbazole method
(μιηοΙ/24 h)
mg/g of creatinine
Uronic acid measured by orcinol method
(μιηοΙ/24 h)
Hexosamine (total) (μηιοΙ/24 h)
Glucosamine (μπιοΙ/24 h)
Galactosamine (μπιοΙ/24 h)
18.96
3.20
19.11
24.11
4.25
19.86
±
±
+
±
±
*
6.18
1.04
5.67
8.50
1.27
7.36
Healthy control
aN = 20
13.39
2.26
13.24
16.81
3.04
13.77
±
±
±
±
±
±
1
0
2
2
0
2
.80
.30
.16
.66
.51
.22
Statistical5 analysis
tcr
tc
tc
tc
ts
= 3.7 :
= 4.1 :
= 3.5 ;
= 3.4 :
= 4.0 :
> tt = 2.
> tt = 2.
> tt = 2.
> tt = 2.
1
1
1
1
> tT = 2.0
a
 N — number of casesb
 For the comparison of the mean values in two populations Fischer's test was primarily used. When Fischer's test indicated
significant differences between variances, the Cohran-Cox test (tc, tt) was used. In other case Student's t test (ts, tT) was applied.
The level p = 0.05 was regarded as significant.
Tab. 3. Electrophoretic analysis of urinary glycosaminoglycans in patients with hypothyroidism and in healthy individuals (mean
±SD)
Healthy control
Hypothyroidism patients
No. of
cases
20
18
Glycosaminoglycans
Total
12.16 + 1.65a
(100)b
17.15 ± 4.94
(100)
Heparan sulphate
2.01 + 0.36
(17)
2.73 + 0.72
(16)
Chondroitin-4/6-sulphate
10.15 H- 1.45
(83)
14.42 + 4.53
(84)
3
 The mean values are expressed as uronic acids (μπιοΙ/24 h)
b
 Numbers in parentheses indicate the percentage of total glycosaminoglycans
were comparable to the changes in their uronic acid
content. In hypothyroidism a significant increase (by
43%) of the total hexosamine level was observed.
Galactosamine and glucosamine contents were in-
creased by 45% and by 39%, respectively (tab. 2).
Glucosamine amounted 18% of total hexosamine in
healthy subjects and 17% in hypothyroidism patients.
The molar ratio of uronic acid/hexosamine was about
0.9 and was the same in the two examined groups.
In addition to the analysis of total uronic acids and
hexosamine, individual glycosaminoglycan fractions
were quantitated after two dimensional electropho-
resis. The results of these experiments are shown in
table 3.
Neither the two dimensional nor the one dimensional
electrophoresis separates chondroitin sulphate iso-
mers. These isomers were therefore quantitated en-
zymatically according to the method of Saito & Mur-
ata. During treatment with chondroitinases and chon-
drosulphatases, urinary chondroitin sulphates in both
examined groups of women were separated into un-
saturated 4-sulphated, 6-sulphated and non sulphated
disaccharides, which were then quantitated.
The amounts of chondroitin sulphate isomers meas-
ured as unsaturated disaccharides are summarized in
table 4.
Tab. 4. Quantitative analysis of chondroitin sulfate isomers
from the urinary glycosaminoglycans in patients with
hypothyroidism and healthy subjects (mean ± SD)
Healthy
control
Chondroitin sulphate ·Ν ! = 17
isomers
Total b11.48 ±2.06
c(100)
Chondroitin-4-sulphate
Derrnatan sulphate
Chondroitin-6-sulphate
Non sulphated chondroitin
sulphate
7.42
(64)
0.20
(2)
3.22
(28)
0.64
(6)
± 1
± 0
± 0
.24
.20
.88
±0.31
Hypothyroidism
patients
aN = 19
15.35
(100)
9.70
(63)
0.24
(1)
4.55
(30)
O.S6
(6)
±
±
±
±
±
5
3
0
1
0
.80
.75
.21
.85
.36
a
 N — number of cases
b
 The mean values are expressed as uronic acids (μηιοΙ/24 h)
c
 lumbers in parentheses indicate the percentage of the total
chondroitin sulphate isomers · ί
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Discussion
Results obtained by different authors concerning the
content and composition of urinary glycosaminogly-
cans in healthy subjects are not consistent. Since uri-
nary glycosaminoglycan excretion is age- and sex-
dependent (23, 24), we chose for our study women in
a narrow age group. In the present work urinary
glycosaminoglycans were isolated using a combined
method. Electrophoretic analysis of urinary glycos-
aminoglycan preparations obtained by the described
procedure reveals a practically pure preparation with-
out any significant glycoprotein contamination. The
results of the current study, using electrophoretic anal-
ysis together with enzymatic hydrolysis, glucosamine
and galactosamine analysis and determination of the
carbazole/orcinol ratio, indicated that the main urine
glycosaminoglycan is chondroitin sulphate and the
minor one is heparan sulphate. The electrophoretic
patterns suggest that part of the main urine glycosa-
minoglycan fraction might be dermatan sulphate.
However, digestion with testicular hyaluronidase and
with chondroitinases, as well as the fact that no ap-
preciable increase of 4-sulphated to 6-sulphated di-
saccharides was found in the degraded products with
chondroitinase ABC over those degraded with chon-
droitinase AC, indicated that there are only small
amounts of dermatan sulphate in both hypothyroid-
ism and control urine samples of glycosaminoglycan
(tab. 4). These findings suggest that the main urine
glycosaminoglycan fraction is largely composed of a
chondroitin-4/6-sulphate type polymer, probably with
low sulphate content. Urinary glycosaminoglycans
may be undersulphated and thus migrate more slowly
than marker samples derived from tissues (25). The
determined composition of urinary glycosaminogly-
can is in agreement with the findings of Yokoi (26),
Goldberg (21) and Nanto-Salonen (28). The mean con-
centration of 24 h urine glycosaminoglycans from
healthy subjects (measured as their uronic acid con-
tent by the carbazole method) was concluded in this
study to be 2.26 + 0.30 mg/g creatinine (13.39 ± 1.80
μιηοΙ/24 h). The yield obtained agrees with those re-
ported by Varma (29), Murata (13) and Bowness (30).
The.borate-carbazole method gives"a low value for
dermatan sulphate and a high value for heparan sul-
phate: 83% and 129% of chondroitin-4-sulphate re-
spectively (22). Because of this known difference in
uronic acid values for the respective polysaccharides,
the urinary glycosaminoglycan content in this report
was also estimated by the orcinol and electrophoretic
methods (tab. 2 and 3). The values of total glycosa-
minoglycan content estimated by electrophoresis (tab.
3) are lower than those obtained by the carbazole and
orcinol methods (tab. 2). Heparan sulphate in urine
may result in a higher recorded value for glycosami-
noglycans by the carbazole method. In the orcinol
reaction iduronic acid gives about 15% higher colour
yield than glucuronic acid (8). In addition to glucu-
ronic acid, heparan sulphate also contains iduronic
acid, and this may be the reason for the higher values
obtained in the orcinol reaction. The percentage of
glucosamine in the total hexosamine corresponded to
the percentage of heparan sulphate in the total gly-
cosaminoglycans estimated by electrophoresis. There-
fore we can state that amount of polysaccharides
estimated by electrophoresis was closer to the real
values than those estimated by the carbazole and
orcinol methods. Also the amounts of urinary chon-
droitin sulphate, based on both electrophoresis and
enzymatic analysis, agreed well with each other. The
sum of unsaturated disaccharides calculated by the
enzymatic method and the amount of chondroitin
sulphate fraction estimated by electrophoresis are not
significantly different. The amounts of disaccharide
subunits derived from urinary glycosaminoglycans
after chondroitinase treatment were approximately
11.5 μιηοΐ per day in normal urine. This value was
within range of the amount reported previously by
Taniguchi (10 μηιοί per day) (22). The molar ratio of
chondroitin-4-sulphate to chondroitin-6-sulphate ob-
tained in this study was 2.3:1, indicating the predom-
inance of chondroitin-4-sulphate in urine chondroitin
sulphate isomers. This is consistent with Taniguchfs
findings (22), but contrary to the results of Murata
et al., which indicated the predominance of chondro-
itin-6-sulphate in human urine (19). Although the
changes in urine glycosaminoglycans in several en-
docrinopathies has been investigated (31), to our
knowledge no information on the content and com-
position of urinary glycosaminoglycans in hypothy-
roidism has hitherto been reported. It is therefore of
interest to investigate any differences that might exist
in terms of glycosaminoglycan excretion between hy-
pothyroidism and healthy subjects. Analysis of our
results shows that significant differences exist between
the mean excretion of glycosaminoglycans in normal
and hypothyroidism subjects, either as total glycosa-
minoglycans or as its separate components. We found
that the concentration of hexuronic acid glycosami-
noglycans in the urine of hypothyroidism patients was
41% higher than in healthy subjects. Heparan sul-
phate and chondroitin-4/6-sulphate levels were 114%
and 42% higher than in a the control group. Chon-
droitin-4-sulphate and chondroitin-6-sulphate in-
creased significantly by 31 % and by 41 % respectively.
The average molar ratio of chondroitin-4-sulphate to
chondroitin-6-sulphate was 2.1:1.0. The percentage
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distribution of chondroitin-4-sulphate, dermatan sul-
phate, chondroitin-6-sulphate and non sulphated
chondroitin sulphate in the total chondroitin sulphate
did not change in the two examined groups.
The urinary glycosaminoglycans are the final degra-
dation products of the proteoglycans found in the
macromolecular matrix of connective tissue. There-
fore the changes observed at the level of the excreted
glycosaminoglycans may reflect the altered metabo-
lism of connective tissue. Several authors have re-
ported an increased content of glycosaminoglycans in
the dermis (5), human aorta wall (32) and other tissues
(6) of patients with hypothyroidism. In our previous
study we observed a decrease of hyaluronidase activity
in the serum of patients with hypothyroidism (33).
The activity of hyaluronidase in the liver, muscle and
skin tissues of animals with experimental hypothy-
roidism was investigated by Martina et al. (34). The
activity of this enzyme was reduced to the 40—50%
of normal. Hyaluronidase degrades hyaluronic acid,
chondroitin-4-sulphate and chondroitin-6-sulphate,
so the reduced activity of this endoglycosidase may
be one of the reasons leading to the accumulation of
the respective types of glycosaminoglycans in tissues
and their high excretion with urine. As some authors
suggested, myxoedematous oedema, loss of hair,
hoarseness and impaired wound healing may all be
due to the quantitative and qualitative changes in
glycosaminoglycans of the mesenchyine (31). Further
investigations are needed to ascertain the mechanism
of these thyroid hormone effects on glycosaminogly-
can metabolism.
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